Rubianthraquinone

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: Rubianthraquinone
• 英文别名: 3,6-dihydroxy-1-methoxy-2-methylanthracene-9,10-dione
• 化学式: C₁₆H₁₂O₅
• 分子量: 284.26
• InChiKey: FDRWSVGPMGRFGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION
  申请人：ETH Zurich

  公开号：EP3943085A2

  公开（公告）日：2022-01-26

  The present invention is directed to a TOMM6 (Translocase of Outer Membrane 6kDa subunit homologue; Mitochondrial import receptor subunit TOM6 homolog)-interacting plant or fungal extract comprising an anthraquinone or anthraquinone derivative, a TOMM6-interacting anthraquinone or anthraquinone derivative, and TOMM6-interacting compounds for use in the treatment or prophylaxis of a nervous system disease, atherosclerosis, Hepatitis B infection and/or human papilloma virus (HPV) infection. Furthermore, the present invention relates to a corresponding method of therapeutic or prophylactic treatment of a nervous system disease or disorder, atherosclerosis, Hepatitis B infection and/or human papilloma virus (HPV) infection, as well as to a method for the identification of a TOMM6-interacting compound or composition. Also, the present invention provides a non-human transgenic animal expressing a transgenic, preferably human TOMM6 or a TOMM6 homolog.

  本发明涉及一种TOMM6（外膜转运酶6kDa亚基同源物；线粒体输入受体亚基TOM6同源物）相互作用的植物或真菌提取物，该提取物包含蒽醌或蒽醌衍生物、与TOMM6相互作用的蒽醌或蒽醌衍生物和与TOMM6相互作用的化合物，用于治疗或预防神经系统疾病、动脉粥样硬化、乙型肝炎感染和/或人类乳头瘤病毒（HPV）感染。此外，本发明还涉及治疗或预防神经系统疾病或紊乱、动脉粥样硬化、乙型肝炎感染和/或人乳头瘤病毒（HPV）感染的相应方法，以及鉴定TOMM6-相互作用化合物或组合物的方法。此外，本发明还提供了一种表达转基因（优选人TOMM6或TOMM6同源物）的非人类转基因动物。
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.